194 related articles for article (PubMed ID: 26077460)
1. Family with MSH2 mutation presenting with keratoacanthoma and precancerous skin lesions.
Hatta N; Takata A; Ishizawa S; Niida Y
J Dermatol; 2015 Nov; 42(11):1087-90. PubMed ID: 26077460
[TBL] [Abstract][Full Text] [Related]
2. Value of MLH1 and MSH2 mutations in the appearance of Muir-Torre syndrome phenotype in HNPCC patients presenting sebaceous gland tumors or keratoacanthomas.
Ponti G; Losi L; Pedroni M; Lucci-Cordisco E; Di Gregorio C; Pellacani G; Seidenari S
J Invest Dermatol; 2006 Oct; 126(10):2302-7. PubMed ID: 16826164
[TBL] [Abstract][Full Text] [Related]
3. Muir-Torre Syndrome and founder mismatch repair gene mutations: A long gone historical genetic challenge.
Ponti G; Manfredini M; Tomasi A; Pellacani G
Gene; 2016 Sep; 589(2):127-32. PubMed ID: 26143115
[TBL] [Abstract][Full Text] [Related]
4. Reduced human mismatch repair protein expression in the development of precancerous skin lesions to squamous cell carcinoma.
Liang SB; Furihata M; Takeuchi T; Sonobe H; Ohtsuki Y
Virchows Arch; 2001 Nov; 439(5):622-7. PubMed ID: 11764381
[TBL] [Abstract][Full Text] [Related]
5. Solitary subungual keratoacanthoma arising in an MSH2 germline mutation carrier: confirmation of a relationship by immunohistochemical analysis.
Stoebner PE; Fabre C; Delfour C; Joujoux JM; Roger P; Dandurand M; Meunier L
Dermatology; 2009; 219(2):174-8. PubMed ID: 19602866
[TBL] [Abstract][Full Text] [Related]
6. [Muir-Torre syndrome and familial colorectal cancer: 2 families with molecular genetic analysis].
Doré MX; Dieumegard B; Grandjouan S; Avril MF; Martinet C; Ducreux M; Lasser P; Bressac-de Paillerets B
Ann Dermatol Venereol; 1999; 126(8-9):582-6. PubMed ID: 10530344
[TBL] [Abstract][Full Text] [Related]
7. Mismatch repair proteins expression and microsatellite instability in skin lesions with sebaceous differentiation: a study in different clinical subgroups with and without extracutaneous cancer.
Cesinaro AM; Ubiali A; Sighinolfi P; Trentini GP; Gentili F; Facchetti F
Am J Dermatopathol; 2007 Aug; 29(4):351-8. PubMed ID: 17667167
[TBL] [Abstract][Full Text] [Related]
8. Clinical and Molecular Features of Skin Malignancies in Muir-Torre Syndrome.
Simic D; Dummer R; Freiberger SN; Ramelyte E; Barysch MJ
Genes (Basel); 2021 May; 12(5):. PubMed ID: 34065301
[TBL] [Abstract][Full Text] [Related]
9. [Muir-Torre syndrome: rare association with duodenal carcinoma].
Bacha D; Deschamps L; Sauvanet A; Couvelard A
Ann Pathol; 2009 Dec; 29(6):495-8. PubMed ID: 20005439
[TBL] [Abstract][Full Text] [Related]
10. HIPK2 expression in progression of cutaneous epithelial neoplasm.
Kwon MJ; Min SK; Seo J; Kim DH; Sung CO; Lim MS; Cho J; Park HR
Int J Dermatol; 2015 Mar; 54(3):347-54. PubMed ID: 25711204
[TBL] [Abstract][Full Text] [Related]
11. [Nuclear DNA analysis of benign skin tumor and carcinoma in site developed from keratinocyte].
Toyoshima H; Hori M; Yoshida H
Nihon Hifuka Gakkai Zasshi; 1991 Apr; 101(5):527-31. PubMed ID: 1890748
[TBL] [Abstract][Full Text] [Related]
12. Muir-torre syndrome with intriguing squamous lesions: a case report and review of the literature.
Nishizawa A; Nakanishi Y; Sasajima Y; Yamazaki N; Yamamoto A
Am J Dermatopathol; 2006 Feb; 28(1):56-9. PubMed ID: 16456327
[TBL] [Abstract][Full Text] [Related]
13. Identification of Muir-Torre syndrome among patients with sebaceous tumors and keratoacanthomas: role of clinical features, microsatellite instability, and immunohistochemistry.
Ponti G; Losi L; Di Gregorio C; Roncucci L; Pedroni M; Scarselli A; Benatti P; Seidenari S; Pellacani G; Lembo L; Rossi G; Marino M; Lucci-Cordisco E; Ponz de Leon M
Cancer; 2005 Mar; 103(5):1018-25. PubMed ID: 15662714
[TBL] [Abstract][Full Text] [Related]
14. A new mutation in Muir-Torre syndrome associated with familiar transmission of different gastrointestinal adenocarcinomas.
Tanyi M; Olasz J; Lukács G; Tanyi JL; Tóth L; Antal-Szalmás P; Ress Z; Bubán T; András C; Damjanovich L
Eur J Surg Oncol; 2009 Oct; 35(10):1128-30. PubMed ID: 19423266
[TBL] [Abstract][Full Text] [Related]
15. Premalignant skin lesions.
Pinkus H; Mehregan AH
Clin Plast Surg; 1980 Jul; 7(3):289-300. PubMed ID: 7438700
[TBL] [Abstract][Full Text] [Related]
16. [Muir-Torre syndrome and Turcot syndrome].
Velter C; Caussade P; Fricker JP; Cribier B
Ann Dermatol Venereol; 2017; 144(8-9):525-529. PubMed ID: 28256262
[TBL] [Abstract][Full Text] [Related]
17. [Mutation in the MSH2 gene in Muir-Torre syndrome].
Godard V; Coulet F; Bernaudin JF; Housset M; Soubrier F
Ann Dermatol Venereol; 1999; 126(8-9):600-3. PubMed ID: 10530347
[TBL] [Abstract][Full Text] [Related]
18. Keratoacanthoma or cutaneous squamous cell carcinoma revealing a DNA mismatch repair default (Muir-Torre Syndrome).
Miao Y; Kolb F; Tomasic G; Lupu J; Routier E; Robert C
J Eur Acad Dermatol Venereol; 2022 Jan; 36 Suppl 1():74-76. PubMed ID: 34855250
[TBL] [Abstract][Full Text] [Related]
19. [Actinic keratosis, Bowen's disease, keratoacanthoma and squamous cell carcinoma of the skin].
Majores M; Bierhoff E
Pathologe; 2015 Feb; 36(1):16-29. PubMed ID: 25663185
[TBL] [Abstract][Full Text] [Related]
20. The importance of functional testing in the genetic assessment of Muir-Torre syndrome, a clinical subphenotype of HNPCC.
Ollila S; Fitzpatrick R; Sarantaus L; Kariola R; Ambus I; Velsher L; Hsieh E; Andersen MK; Raevaara TE; Gerdes AM; Mangold E; Peltomäki P; Lynch HT; Nyström M
Int J Oncol; 2006 Jan; 28(1):149-53. PubMed ID: 16327991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
